These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 25707393)

  • 1. Pharmacogenomic information in drug labels: European Medicines Agency perspective.
    Ehmann F; Caneva L; Prasad K; Paulmichl M; Maliepaard M; Llerena A; Ingelman-Sundberg M; Papaluca-Amati M
    Pharmacogenomics J; 2015 Jun; 15(3):201-10. PubMed ID: 25707393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing cytochrome P450 pharmacogenetic information available on United States drug labels and European Union Summaries of Product Characteristics.
    Reis-Pardal J; Rodrigues A; Rodrigues E; Fernandez-Llimos F
    Pharmacogenomics J; 2017 Dec; 17(6):488-493. PubMed ID: 27241061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomic biomarkers in drug labels: what do they tell us?
    Tutton R
    Pharmacogenomics; 2014 Feb; 15(3):297-304. PubMed ID: 24533709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Current Regulation and Guidelines of Pharmacogenomic Drug Labels: Opportunities for Improvements.
    Shekhani R; Steinacher L; Swen JJ; Ingelman-Sundberg M
    Clin Pharmacol Ther; 2020 May; 107(5):1240-1255. PubMed ID: 31715018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetic information in Swiss drug labels - a systematic analysis.
    Jeiziner C; Suter K; Wernli U; Barbarino JM; Gong L; Whirl-Carrillo M; Klein TE; Szucs TD; Hersberger KE; Meyer Zu Schwabedissen HE
    Pharmacogenomics J; 2021 Aug; 21(4):423-434. PubMed ID: 33070160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How pharmacogenomics (PG) are changing practice: implications for prescribers, their patients, and the healthcare system (PG series part I).
    Preskorn SH; Hatt CR
    J Psychiatr Pract; 2013 Mar; 19(2):142-9. PubMed ID: 23507814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomic Biomarkers: an FDA Perspective on Utilization in Biological Product Labeling.
    Schuck RN; Grillo JA
    AAPS J; 2016 May; 18(3):573-7. PubMed ID: 26912182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomic information in the Warning section of drug labels: A comparison between labels in the United States and those in five other countries/regions.
    Imatoh T; Sai K; Saito Y
    J Clin Pharm Ther; 2018 Aug; 43(4):493-499. PubMed ID: 29682780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenomic information from CPIC and DPWG guidelines and its application on drug labels.
    Yoon DY; Lee S; Ban MS; Jang IJ; Lee S
    Transl Clin Pharmacol; 2020 Dec; 28(4):189-198. PubMed ID: 33425802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in pharmacogenomic biomarker information in package inserts from the United States, the United Kingdom and Japan.
    Shimazawa R; Ikeda M
    J Clin Pharm Ther; 2013 Dec; 38(6):468-75. PubMed ID: 23895776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.
    Frueh FW; Amur S; Mummaneni P; Epstein RS; Aubert RE; DeLuca TM; Verbrugge RR; Burckart GJ; Lesko LJ
    Pharmacotherapy; 2008 Aug; 28(8):992-8. PubMed ID: 18657016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applications of pharmacogenomics in regulatory science: a product life cycle review.
    Tan-Koi WC; Leow PC; Teo YY
    Pharmacogenomics J; 2018 May; 18(3):359-366. PubMed ID: 29205206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translation of pharmacogenomic drug labels into the clinic. Current problems.
    Ingelman-Sundberg M
    Pharmacol Res; 2020 Mar; 153():104620. PubMed ID: 31899313
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacogenomic biomarker information differences between drug labels in the United States and Hungary: implementation from medical practitioner view.
    Varnai R; Szabo I; Tarlos G; Szentpeteri LJ; Sik A; Balogh S; Sipeky C
    Pharmacogenomics J; 2020 Jun; 20(3):380-387. PubMed ID: 31787752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Learning from product labels and label changes: how to build pharmacogenomics into drug-development programs.
    Surh LC; Pacanowski MA; Haga SB; Hobbs S; Lesko LJ; Gottlieb S; Papaluca-Amati M; Patterson SD; Hughes AR; Kim MJ; Close SL; Mosteller M; Zineh I; Dechairo B; Cohen NA
    Pharmacogenomics; 2010 Dec; 11(12):1637-47. PubMed ID: 21142906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenomic information in FDA-approved drug labels: Application to pediatric patients.
    Green DJ; Mummaneni P; Kim IW; Oh JM; Pacanowski M; Burckart GJ
    Clin Pharmacol Ther; 2016 Jun; 99(6):622-32. PubMed ID: 26693845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA, drugs and chariots: on a decade of pharmacogenomics at the US FDA.
    Lesko LJ; Zineh I
    Pharmacogenomics; 2010 Apr; 11(4):507-12. PubMed ID: 20350131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenomic biomarker information on drug labels of the Spanish Agency of Medicines and Sanitary products: evaluation and comparison with other regulatory agencies.
    Estévez-Paredes M; Mata-Martín MC; de Andrés F; LLerena A
    Pharmacogenomics J; 2024 Jan; 24(1):2. PubMed ID: 38233388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenomic biomarkers: Interpretation of information included in United States and Japanese drug labels.
    Shimazawa R; Ikeda M
    J Clin Pharm Ther; 2018 Aug; 43(4):500-506. PubMed ID: 29722046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variability of Pharmacogenomics Information in Drug Labels Approved by Different Agencies and its Ethical Implications.
    Güner MD; Ekmekci PE; Kurtoglu B
    Curr Drug Saf; 2022; 17(1):47-53. PubMed ID: 34315387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.